NCT05588804View on ClinicalTrials.gov

Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

556

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

December 18, 2022

Study Completion Date

December 18, 2022

Conditions
Acute Uncomplicated Respiratory Tract Infections
Interventions
DRUG

Broncho-munal®

1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days

DRUG

Placebo

1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days

Trial Locations (13)

117321

Sandoz Investigative Site, Moscow

194156

Sandoz Investigative Site, Saint Petersburg

194354

Sandoz Investigative Site, Saint Petersburg

194358

Sandoz Investigative Site, Saint Petersburg

195197

Sandoz Investigative Site, Saint Petersburg

196143

Sandoz Investigative Site, Saint Petersburg

197136

Sandoz Investigative Site, Saint Petersburg

197198

Sandoz Investigative Site, Saint Petersburg

197342

Sandoz Investigative Site, Saint Petersburg

197706

Sandoz Investigative Site, Saint Petersburg

198328

Sandoz Investigative Site, Saint Petersburg

199226

Sandoz Investigative Site, Saint Petersburg

603140

Sandoz Investigative Site, Nizhny Novgorod

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT05588804 - Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections | Biotech Hunter | Biotech Hunter